Keros Therapeutics Inc (KROS)

Keros Therapeutics Inc (KROS) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $222M; returns 1 day -0.6%, 1 week +5.8%, 1 year -24.2%.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders. Their research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production.

Groups KROS belongs to

• Biotechnology
• Clinical Stage Biopharma
• Healthcare
• Hematology
• Biopharmaceutical
• Clinical Stage Biotech
• Life Sciences
• Rare Diseases
• Hematologic Malignancies

KROS financial model: income statement, cash flow and balance sheet